Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
An open-labelled, uncontrolled, single-center Phase I/IIa clinical study to evaluate the
safety of repeated infusions of AdVince into the hepatic artery in patients with metastatic
neuroendocrine tumors (NETs), and if possible determination of maximum tolerated dose.